Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

794
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
794
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

538
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
538
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

213
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
213
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

354
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
354

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of auricular vagal neuromodulation therapy combined with slow-paced diaphragmatic breathing in individuals with postural tachycardia syndrome: a randomised controlled trial protocol.

BMJ open·2026
Same author

Management of dyslipidaemia in patients with comorbidities - facing the challenge: Heart failure.

European heart journal. Cardiovascular pharmacotherapy·2026
Same author

Associations of ANGPTL3/4/8 proteins and complexes with heart failure and heart failure mortality.

Lipids in health and disease·2026
Same author

Identification of potentially heat-vulnerability increasing drugs - a narrative review.

European journal of clinical pharmacology·2026
Same author

[Consensus statement of the Austrian Society for Rheumatology and Rehabilitation on the management of increased cardiovascular risk in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis].

Wiener klinische Wochenschrift·2026
Same author

Aspirin after PCI in Acute Coronary Syndromes.

The New England journal of medicine·2026

Related Experiment Video

Updated: Jan 15, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.8K

Routinely Available Inflammatory Biomarkers Are Not Associated With Target Lesion Revascularization After Coronary

Eva Steinacher1, Andreas Hammer1, Ulrike Baumer1

  • 1Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.

JACC. Advances
|October 15, 2025
PubMed
Summary

Systemic inflammation predicts mortality after percutaneous coronary intervention (PCI), but not target lesion revascularization or stent thrombosis. Elevated inflammatory markers should not delay PCI with modern stents.

Keywords:
C-reactive proteinacute stent thrombosisinflammationleukocytespercutaneous coronary interventiontarget lesion revascularization

More Related Videos

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.7K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.6K

Related Experiment Videos

Last Updated: Jan 15, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.8K
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.7K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.6K

Area of Science:

  • Cardiology
  • Inflammation Research
  • Interventional Cardiology

Background:

  • Biomarkers of inflammation predict adverse cardiovascular events in coronary artery disease.
  • The link between systemic inflammation and percutaneous coronary intervention (PCI)-related adverse events is unclear.

Purpose of the Study:

  • To investigate the association of C-reactive protein, leukocytes, and neutrophil-to-lymphocyte ratio (NLR) with patient outcomes after PCI.
  • To determine if inflammatory biomarkers predict PCI-related adverse events in an unselected patient cohort.

Main Methods:

  • Observational trial of 7,412 patients undergoing PCI.
  • Median follow-up of 4.6 years.
  • Primary endpoints: target lesion revascularization (TLR) and acute stent thrombosis (ST). Secondary endpoints: mortality and major adverse cardiovascular events (MACE). Cox regression analysis used.

Main Results:

  • No association found between systemic inflammation and TLR or acute ST.
  • Inflammatory biomarkers were significantly associated with all-cause mortality, cardiovascular mortality, and MACE.
  • Adjusted hazard ratios for C-reactive protein showed no significant relation to TLR or ST.

Conclusions:

  • Systemic inflammation is important for predicting mortality and MACE after PCI.
  • Elevated baseline inflammatory parameters do not correlate with TLR or acute ST.
  • PCI should not be delayed based on inflammatory markers in the era of second-generation drug-eluting stents.